Addex Therapeutics
NASDAQ: ADXNGeneva · Switzerland corporation · 4 known investors
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtech
Founders & leadership
RM
Roger MillsExecutive
MK
Mikhail KalinichevExecutive
JR
Jean-Philippe RocherExecutive
RL
Robert LutjensExecutive
TD
Timothy DyerExecutive
VL
Vincent LawtonNamed on SEC filing
JN
Jake NunnNamed on SEC filing
RH
Raymond HillNamed on SEC filing
Board
IM
Investors · 4
Reported raises · per SEC filings
Form D private placements$13.9M disclosed across 3 rounds · 2021–2023
▶$3.7MraisedApr 2023 · 1 investors · BiotechnologyRule 506(b)
▶$3.7MraisedApr 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean-Philippe RocherExecutive Officer
- Vincent LawtonDirector
- Mikhail KalinichevExecutive Officer
- Jake NunnDirector
- Timothy DyerExecutive Officer, Director
- Isaac MankeDirector
- Robert LutjensExecutive Officer
- Raymond HillDirector
- Roger MillsExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Apr 2023
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
▶$4.2MraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
▶$4.2MraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roger MillsExecutive Officer, Director
- Mikhail KalinichevExecutive Officer
- Isaac MankeDirector
- Jean-Philippe RocherExecutive Officer
- Vincent LawtonDirector
- Jake NunnDirector
- Raymond HillDirector
- Robert LutjensExecutive Officer
- Timothy DyerExecutive Officer, Director
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $285.6K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2022
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
▶$5.9MraisedDec 2021 · 1 investors · BiotechnologyRule 506(b)
▶$5.9MraisedDec 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LutjensExecutive Officer
- Raymond HillDirector
- Roger MillsExecutive Officer, Director
- Mikhail KalinichevExecutive Officer
- Jake NunnDirector
- Jean-Philippe RocherExecutive Officer
- Timothy DyerExecutive Officer, Director
- Isaac MankeDirector
- Vincent LawtonDirector
- Offering amount
- $5.9M
- Amount sold
- $5.9M
- Sales commissions
- $400.6K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2021
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapAdcentrx Therapeutics18 shared keywordsAdcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology. It develops site-specific ADC therapeutics and supporting platform technology for cancer treatment.
Celldex Therapeutics, Inc.15 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Adarx14 shared keywordsADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes. Its pipeline targets chronic conditions including genetic, complement-mediated, cardiovascular, cardiometabolic, central nervous system, and metabolic diseases.
Exelixis14 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with Addex Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Addex Therapeutics do?
- Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
- Who are Addex Therapeutics's investors?
- Addex Therapeutics's investors include New Enterprise Associates (NEA), Sofinnova Partners, ACORN BIOVENTURES, SR One Capital Management.
- How much funding has Addex Therapeutics raised?
- Addex Therapeutics has disclosed $13.9M raised across 3 rounds.
- Where is Addex Therapeutics headquartered?
- Addex Therapeutics is headquartered in Geneva.